Trelstar 22.5mg is a six-month slow release, injectable, luteinizing hormone-releasing hormone agonist indicated for the palliative treatment of advanced prostate cancer.
Paladin obtained the Canadian license for Trelstar from Watson Pharma, a subsidiary of Watson Pharmaceuticals in May 2005.
Jonathan Goodman, president and CEO of Paladin Labs, said: “Trelstar is an important component of Paladin’s urology franchise and this new dosage form will further strengthen this portfolio.”